WINTON GROUP Ltd Takes $1.02 Million Position in Black Diamond Therapeutics, Inc. $BDTX

Posted by Brenda Bartman on Jun 10th, 2026

WINTON GROUP Ltd bought a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 421,280 shares of the company’s stock, valued at approximately $1,024,000. WINTON GROUP Ltd owned approximately 0.74% of Black Diamond Therapeutics at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Geode Capital Management LLC grew its stake in shares of Black Diamond Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 505,780 shares of the company’s stock valued at $1,229,000 after acquiring an additional 5,257 shares in the last quarter. Kathmere Capital Management LLC grew its stake in Black Diamond Therapeutics by 31.0% in the fourth quarter. Kathmere Capital Management LLC now owns 31,822 shares of the company’s stock worth $77,000 after purchasing an additional 7,539 shares in the last quarter. Bank of America Corp DE grew its stake in Black Diamond Therapeutics by 22.5% in the third quarter. Bank of America Corp DE now owns 43,359 shares of the company’s stock worth $164,000 after purchasing an additional 7,972 shares in the last quarter. Cerity Partners LLC acquired a new position in Black Diamond Therapeutics in the second quarter worth about $26,000. Finally, Virtu Financial LLC acquired a new position in Black Diamond Therapeutics in the third quarter worth about $39,000. 95.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDTX has been the subject of a number of research reports. Wall Street Zen downgraded Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Raymond James Financial reiterated an “outperform” rating on shares of Black Diamond Therapeutics in a research note on Friday, May 22nd. BTIG Research lifted their price target on Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. HC Wainwright reiterated a “buy” rating on shares of Black Diamond Therapeutics in a research note on Friday, May 22nd. Finally, Wedbush lifted their price target on Black Diamond Therapeutics from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Black Diamond Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Check Out Our Latest Analysis on Black Diamond Therapeutics

Black Diamond Therapeutics Stock Up 2.7%

Shares of NASDAQ BDTX opened at $1.90 on Wednesday. The firm’s 50-day moving average price is $2.62 and its two-hundred day moving average price is $2.59. Black Diamond Therapeutics, Inc. has a 52-week low of $1.85 and a 52-week high of $4.94. The stock has a market capitalization of $108.87 million, a P/E ratio of -2.47 and a beta of 3.22.

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. As a group, equities research analysts expect that Black Diamond Therapeutics, Inc. will post -0.6 earnings per share for the current year.

Black Diamond Therapeutics Company Profile

(Free Report)

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.